The remarkable infectivity and virulence of the 1918 influenza virus resulted in an unprecedented pandemic, raising the question of whether it is possible to develop protective immunity to this virus and whether immune evasion may have contributed to its spread. Here, we report that the highly lethal 1918 virus is susceptible to immune protection by a preventive vaccine, and we define its mechanism of action. Immunization with plasmid expression vectors encoding hemagglutinin (HA) elicited potent CD4 and CD8 cellular responses as well as neutralizing antibodies. Antibody specificity and titer were defined by a microneutralization and a pseudotype assay that could assess antibody specificity without the need for high-level biocontainment. This pseudotype inhibition assay can define evolving serotypes of influenza viruses and facilitate the development of immune sera and neutralizing monoclonal antibodies that may help contain pandemic influenza. Notably, mice vaccinated with 1918 HA plasmid DNAs showed complete protection to lethal challenge. T cell depletion had no effect on immunity, but passive transfer of purified IgG from anti-H1(1918) immunized mice provided protective immunity for naïve mice challenged with infectious 1918 virus. Thus, humoral immunity directed at the viral HA can protect against the 1918 pandemic virus.
influenza vaccines ͉ neutralizing antibody ͉ vaccines I n the past century, three influenza outbreaks have caused significant increases in human fatalities throughout the world, the hallmark of pandemics. Among them, the 1918 strain was notable for its exceptional infectivity and disease severity in otherwise healthy individuals, with mortality of 40 million to 50 million people worldwide. Through molecular analysis of preserved specimens, it has been possible to characterize the gene products of this virus in an effort to determine the molecular basis for its immunopathogenesis (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Recently, this virus was reconstructed fully from lung specimens stored in 1918 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) and shown to cause highly lethal infection in mice. This model has provided an opportunity to analyze the genetic basis of its virulence and to explore mechanisms of immunity relevant to the development of vaccines and antivirals for this and other influenza viruses with pandemic potential. Specifically, we sought to determine whether it is possible to generate protective immunity to this virus, to define potential mechanisms of immune protection, and to ascertain whether countermeasures can be developed to contain outbreaks.
Results

Generation of Expression Vectors.
To evaluate the protective immune response against the 1918 influenza virus, synthetic plasmid expression vectors encoding HA were generated. Plasmids expressing wild-type (WT) hemagglutinin (HA) (GenBank accession no. DQ868374) or HA with a mutation in the HA cleavage site (GenBank no. DQ868375) that attenuates influenza virus during viral replication were prepared by using nonviral codons, both to ensure compatibility with mammalian codon usage and to exclude the unlikely possibility of homologous reassortment with WT influenza viruses that might generate replication-competent H1(1918) virus (Fig. 1A) . Expression was confirmed in transfected human renal 293T cells by Western blot analysis using antisera from mice vaccinated with these DNA expression vectors (Fig. 1B) .
Vaccination with DNA Vaccines and Analysis of Cellular Immune
Responses. Antisera to the 1918 HA were generated by intramuscular inoculation of BALB/c mice with DNA vaccines. DNA vaccines included the WT 1918 HA as well as an attenuated HA(1918) cleavage site (⌬CS) mutant (Fig. 1 A) . Immunization with HA induced significant cellular and humoral responses. For example, H1(1918)⌬CS induced a Ͼ10-fold increase in H1(1918)-specific antibody measured by ELISA ( Fig. 2A Left) . The neutralization activity was confirmed by the microneutralization assay using live 1918 (H1N1) virus (Fig. 2 A Right) . Neutralization titers of Ϸ1:80 were observed with both the WT (data not shown) and mutant HA expression vectors using this assay, with a modest increase in the neutralization titers observed with the attenuated cleavage site mutant. Next, the cellular immune response was characterized in immunized mice. Vaccinated animals showed a marked increase in H1 (1918) antigen-specific CD4 and CD8 T cells (Fig. 2B) , as determined by intracellular cytokine staining to measure cells synthesizing either IFN-␥ and͞or TNF-␣, at levels at least 62-fold and 122-fold above the background response for each T cell subset, respectively. These responses compared favorably with those observed with other viral spike proteins, including HIV, severe acute respiratory syndrome (SARS), coronavirus, and Ebola virus, all of which contain a number of predicted T cell epitopes (data not shown). (Fig. 3A Lower) . To define the mechanism of immune protection, T cell depletion was performed with monoclonal antibodies [anti-mouse CD4(GK1.5), anti-mouse CD8(2.43), or anti-mouse CD90(30-H12)] to CD4, CD8, and Immune protection conferred against lethal challenge of 1918 influenza and lack of T cell dependence. (A) Immunization with H1(1918), H1(1918)⌬CS, or negative control plasmid expression vectors was performed in mice (n ϭ 10 per group) as described (11) , and survival (Upper) and weight loss (Lower) were evaluated. The statistical significance between these groups are P ϭ 1.08 ϫ 10 Ϫ5 and P ϭ 1.08 ϫ 10 Ϫ5 with respect to controls by Fisher's exact test. (B) Monoclonal rat anti-mouse anti-CD4, CD8, and CD90 (T cell depletion) were used to deplete T cells in H1(1918)⌬CS immunized mice, in comparison with a control group of vaccinated animals injected with nonimmune IgG (Control IgG). Vector-immunized animals that received no depletion served as additional controls (Vector). Mice were administered IgG at Ϫ3, ϩ3, ϩ9, and ϩ15 days after viral challenge. Mice (n ϭ 10 per group) were then evaluated for survival (Upper) and weight loss (Lower). No decrease in immune protection was observed in T cell-depleted animals. CD90 (Thy1.2), previously shown to deplete Ͼ99% T cells in lung and spleen (12) . The same negative control DNA plasmid vectors without an insert were used for both the DNA vaccine and the depletion studies. T cell depletion of H1(1918) immunized animals did not affect survival (Fig. 3B Upper) , and these mice showed weight loss comparable with nonimmune Ig-treated animals (Fig. 3B Lower) . In contrast, when IgG from immunized mice purified by Protein A chromatography was passively transferred to naïve recipients, neutralizing antibodies could be detected in the recipients at levels slightly below those of the immunized mice (Fig. 4A vs. Fig. 2 A Left) . Importantly, passive transfer of this immune IgG conferred immune protection in 8 of 10 mice, compared with 0 of 10 animals that received IgG from control unvaccinated animals ( Fig. 4B ; P ϭ 0.0007).
Development of Pseudotyped Lentiviral Reporters. The functional activity of this HA was assessed through the use of a pseudotyped lentiviral vector in which the 1918 HA was used instead of the retroviral envelope. The HA pseudoviruses were then characterized for their susceptibility to neutralizing antibodies by using a luciferase reporter gene. Whereas H5-pseudotyped lentiviral vectors readily mediated entry, the H1(1918) strain was inactive (Fig. 5A Left vs. Center, second column). Because H5 viruses contain a cleavage site recognized more broadly by proteases, the protease cleavage site region from H5 was substituted into the relevant sequence of H1 (1918) in an effort to increase its processing to a fusion-competent form.
A modification that extended 11 aa (Fig. 1 A; H5⌬PS2 ) from the cleavage site improved entry more than a slightly shorter 9-aa (Fig. 1 A; H5⌬PS ) addition (Fig. 5A Center, third and fourth column). Insertion of an H5 cleavage site conferred a similar increase in entry for an independent H1 strain, PR/8 (Fig. 5A  Right) , suggesting that such modifications could allow otherwise incompetent HAs to generate functionally active pseudotyped vectors that could be used to assess neutralizing antibody activity.
Humoral immunity in mice immunized with 1918 HA plasmid DNAs was assessed by using the viral pseudotype assay. To analyze the ability of antibodies to neutralize virus, the pseudoviruses were incubated with antisera from control and HAimmune animals, and the reduction in luciferase activity was measured. Sera from animals immunized with the H1(1918) or H5(Kan-1) HA expression vectors neutralized pseudotyped lentiviral vectors encoding the homologous, but not the heterologous, HAs at dilutions of 1:400 in this assay, in contrast to nonimmune sera, which had no effect (Fig. 5B) . These titers were considerably higher than those measured by microneutralization ( Fig. 2A) or hemagglutination inhibition (data not shown), suggesting that the pseudotype vector inhibition assay is more sensitive. Thus, immunity in the lethal challenge model was readily measured and correlated with protection in this assay.
Discussion
In this study, gene-based vaccination was used to elicit cellular and humoral immune responses to the 1918 influenza virus HA. The humoral immune response was able to neutralize this virus, and these antibodies were necessary and sufficient to confer protective immunity to lethal challenge by virus. In contrast, although a robust T cell response was observed, this response was not required for protective immunity. Whereas slightly increased weight loss was observed in T cell-depleted animals relative to controls, this difference was also observed to some extent in control animals, likely reflecting stress associated with the additional manipulations. Thus, although it remains possible that T cells may contribute to an antiviral effect and could potentially contribute to cross-heterotypic protection to variant viruses, they are not required for immune protection for this vaccine in the mouse. In humans, immune control is likely also antibody dependent, but we cannot exclude the possibility that cellular mechanisms of protection may contribute to viral clearance. The unique circumstances that contributed to the 1918 pandemic spread are also unknown. Although there has been speculation about the types of viruses that may have circulated before the epidemic and their implications for herd immunity, neither the virus isolates nor sera from these times are available, and the present epidemiologic data do not permit further analysis, although recovery of such viruses through methods used for the 1918 rescue could be informative in the future.
The ability to use a pseudotyped lentiviral vector with viral HA allows for analysis of neutralizing antibody response with increased sensitivity in the detection of neutralizing antibodies compared with the traditional antiviral assay. In addition, the ability to perform screening in the absence of replicationcompetent virus allows for methods to screen for neutralizing antibodies and to generate antiviral reagents, for the 1918 pandemic influenza virus, as well as avian H5N1 influenza virus and other possibly highly pathogenic influenza viruses in a conventional biosafety level 2 laboratory. It will also be desirable in the future to compare results from this assay with hemagglutination inhibition to explore its ability to predict protective immunity in humans. However, the difficulty of preparing large quantitities of the highly pathogenic H1N1 virus make it technically infeasible at this time.
Further testing will be required to determine whether DNA vaccination can confer similar humoral immune responses in humans and to assess the response. Previous experience has shown that this mode of vaccination is much less effective in humans than in rodents and thus may not be the preferred form of the 1918 H1N1 vaccine. The results nonetheless demonstrate that humoral immune responses are protective against viral infection and provide proof of concept that immunization with H1(1918), whether by gene-based vaccines, recombinant proteins, or inactivated virus, is likely to be successful for the generation of protective immunity in humans. These data also suggest that there is no intrinsic immune resistance of this pandemic influenza virus. This knowledge, together with the enhanced ability to measure and screen for neutralizing antibody as a correlate of protection, will facilitate the development of novel protective vaccines and monoclonal antibodies for the 1918 influenza virus and for contemporary pandemic flu threats.
Materials and Methods
Immunogen and Plasmid Construction. Plasmids encoding different versions of HA protein [A/South Carolina/1/18, GenBank AF117241; A/Thailand/1(KAN-1)/2004, GenBank AAS65615; A/PR/8/34, GenBank P03452] were synthesized by using humanpreferred codons as described (12) by GeneArt (Regensburg, Germany). All of the H1 and H5 HA cleavage-site mutants were made with the original viral cleavage amino acid sequences changed to PQRETRG, ⌬CS, which is originally from a low-pathogenicity H5 isolate (A/chicken/Mexico/31381/94; GenBank AAL34297), and the modification resulted in the trypsin-dependent phenotype (13) and may alter the antigenic character. To make the pseudotyped lentiviral vector for H1(1918), the original viral cleavage site was changed to IPQRERRRKKRG, ⌬PS, and SPQR-ERRRKKRG, ⌬PS2, which is originally from a highly virulent H5 [A/Thailand/1(KAN-1)/2004], and the modification should result in the trypsin-independent phenotype. Protein expression was confirmed by Western blot analysis (14) with serum from mice immunized with HA-expressing plasmid DNA.
To synthesize the coating antigen for the ELISA, codonoptimized cDNA corresponding to aa 1 to 530 was cloned into CMV/R 8〉 expression vector for efficient expression in mammalian cells. This vector utilizes the CMV/R plasmid backbone (15) with several modifications at the NF-B binding sites in the enhancer/promoter region to enhance immunogenicity of the inserts expressed in the plasmid DNA constructs. Four B binding sites in the enhancer/promoter region were modified by two pairs to a consensus B sequence (16) as follows: nucleotide (nt) 802 GCACCAAAATCAACGGGACTTT was changed to ACTCAC-CAAAATCAACGGGAATTC; nt 753 GGGGATTT was changed to GGGACTT; nt 648 GGGACTTT was changed to GGGAATTT; and nt 607 TAAATGGCCCGCCTG was changed to GAACTTCCATAAGCTT. Two additional such sites were introduced upstream of the original enhancer/promoter region as follows: nt 550 GGCAGTACATCA was changed to GGGAATT-TCCA; nt 497 GGGACTTTC was changed to GGGAACTTC; nt 714 TAAATGGCGGG was changed to GAATTTCCAAA; and nt 361 GGGGTCATTAGTT was changed to GGGAACTTC. When tested in mice, a CMV/R 8B plasmid induced a higher immunological response to HIV clade B envelope immunogen, with higher antigen-specific CD4 and CD8 T cell responses than CMV/R, and also improved antibody responses (data not shown). A trimerization sequence from bacteriophage T4 fibritin was introduced followed by a thrombin cleavage site and a His tag at the C terminus. The plasmid was then transfected into 293T cells, and the cell media containing the secreted protein was collected and purified by nickel column chromatography. The purified protein contains the following additional residues at the C terminus (RSLVPRGSPGSGYIPEAPRDGQAYVRKDGEWVLLSTFL-GHHHHHH), where the thrombin site is in italics, the fibritin trimerization sequence is underlined, and the His tag is in bold. Similar modifications used for HA molecule structural studies have been described (7).
Vaccination. Female BALB/c mice (6-8 weeks old; Jackson Laboratories, Bar Harbor, ME) were immunized intramuscularly with 15 g of plasmid DNA in 100 l of PBS (pH 7.4) at weeks 0, 3, and 6 for T lymphocyte depletion, IgG passive transfer, and viral challenge. T cell depletion and antibody transfer were performed as described below. An additional immunization at week 12 was performed in groups for the intracellular cytokine staining assay.
Flow Cytometric Analysis of Intracellular Cytokines. CD4
ϩ and CD8 ϩ T cell responses were evaluated by using intracellular cytokine staining for IFN-␥ and TNF-␣ as described (14) with peptide pools (15 mers overlapping by 11 aa, 2.5 g/ml each) covering the HA protein. Cells were then fixed, permeabilized, and stained by using rat monoclonal anti-mouse CD3, CD4, CD8, IFN-␥, and TNF-␣ (BD-PharMingen, San Diego, CA). The IFN-␥-and TNF-␣-positive cells in the CD4
ϩ and CD8 ϩ cell populations were analyzed with the program FlowJo (Tree Star, Ashland, OR).
ELISA for Mouse Anti-HA IgG and IgM. The mouse anti-HA IgG and IgM ELISA titer was measured by using a described method (17) . Purified HA protein was made by purification of a transmembrane-domain-truncated HA protein with a trimerization domain, thrombin cleavage site, and His tag expressed in the CMV/R 8B expression vector. H1 or H5 protein was purified
